May 2018 $17 M No. 5 $10 to $50 million 43
Pressure Biosciences Inc.: Raise no. 5, May 2018 × Investors in this round 43 investors had bought by the notice of Mar 20, 2019: 43 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Pressure Biosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $17 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue $1 million to $5 million
Sales commissions $416,300
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Massachusetts People named in the notice Richard P. Thomley · Executive Officer · Acting Chief Financial Officer Richard T. Schumacher · Executive Officer, Director · President, Chief Executive Officer, Treasurer and Clerk Jeffrey N. Peterson · Director · Chairman of the Board Kevin A. Pollack · Director Michael S. Urdea · Director · Chairman of the Board Vito J. Mangiardi · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Garden State Securities, Inc. · Red Bank, New Jersey Sold in all US states Remarks in the notice On fees: “Warrants for 318,680 shares with an exercise price of $3.50 per share were issued to Garden State as compensation in addition to their sales commissions.”On the amounts: “From May 2, 2018 through March 6, 2019, the Company sold the securities detailed in Item 9 for a total purchase price of $4,288,000. During the same period, the company converted debt equal to $13,171,551 into the securities detailed in Item 9.”Signed by Richard T. Schumacher, President, CEO, Treasurer, Clerk and Director. Source: SEC Form D, newest notice filed Mar 20, 2019. Read the notice at the SEC .
equity, options SEC Jul 2015 $5 M No. 4 $2 to $10 million 22
Pressure Biosciences Inc.: Raise no. 4, Jul 2015 × Investors in this round 22 investors had bought by the notice of Jan 27, 2016: 22 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Pressure Biosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $6 M offered; $1 M still to sell
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions $460,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Massachusetts People named in the notice Richard Schumacher · Executive Officer, Director · President and Chief Executive Officer Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Garden State Securities, Inc. (CRD 10083) · Red Bank, New Jersey Sold in CA, IA, ID, IL, MD, NC, NJ, NY, RI, VA, WA Signed by Richard Schumacher, President, CEO and Director. Source: SEC Form D, newest notice filed Jan 27, 2016. Read the notice at the SEC .
equity, options SEC Feb 2013 $2 M No. 3 Under $2 million 17
Pressure Biosciences Inc.: Raise no. 3, Feb 2013 × Investors in this round 17 investors had bought by the notice of Feb 21, 2013: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Pressure Biosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered; $0 M still to sell
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Massachusetts People named in the notice Alexander P. Lazarev · Executive Officer Conrad F. Mir · Executive Officer Edmund Y. Ting · Executive Officer Nathan P. Lawrence · Executive Officer Richard T. Schumacher · Executive Officer, Director Jeffrey N. Peterson · Director Kevin A. Pollack · Director Michael S. Urdea · Director Vito J. Mangiardi · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “$590,000 was received in cash and $1,112,800 was from the conversion of outstanding indebtedness and accrued board of directors' fees.”Signed by Richard Schumacher, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 21, 2013. Read the notice at the SEC .
equity, options SEC Nov 2009 $2 M No. 2 Under $2 million 31
Pressure Biosciences Inc.: Raise no. 2, Nov 2009 × Investors in this round 31 investors had bought by the notice of Apr 1, 2010: 31 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Pressure Biosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $3 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees $100,478
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Massachusetts People named in the notice Alexander P Lazarev · Executive Officer Edmund Y Ting · Executive Officer Matthew B Potter · Executive Officer Nathan P Lawrence · Executive Officer Richard T Schumacher · Executive Officer, Director Alan Donald Rosenson · Director Calvin A Saravis · Director J Donald Payne · Director R Wayne Fritzsche · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Lantern Investments, Inc. (CRD 30996) · Melville, Ny Sold in no state named Remarks in the notice On fees: “In addition, the finder received warrants to purchase an aggregate of 5,344 shares of Series B Convertible Preferred Stock at $28.80 per share, which warrants expire on August 11, 2012.”Signed by Richard T. Schumacher, President and CEO. Source: SEC Form D and 1 amendment, newest notice filed Apr 1, 2010. Read the notice at the SEC .
equity, options SEC Feb 2009 $2 M No. 1 Under $2 million 35
Pressure Biosciences Inc.: Raise no. 1, Feb 2009 × Investors in this round 35 investors had bought by the notice of Feb 24, 2009: 35 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Pressure Biosciences Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $4 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Ma People named in the notice Alexander Lazarev · Executive Officer Edmund Y Ting · Executive Officer Matthew B Potter · Executive Officer Nathan P Lawrence · Executive Officer Richard T Schumacher · Executive Officer, Director Calvin A Saravis · Director J Donald Payne · Director P Thomas Vogel · Director R Wayne Fritzsche · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Richard T. Schumacher, President and CEO. Source: SEC Form D, newest notice filed Feb 24, 2009. Read the notice at the SEC .
equity, options SEC